Literature DB >> 21450988

Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS.

Johanna Puurunen1, Terhi Piltonen, Laure Morin-Papunen, Antti Perheentupa, Ilkka Järvelä, Aimo Ruokonen, Juha S Tapanainen.   

Abstract

CONTEXT: Women with polycystic ovary syndrome (PCOS) are known to suffer from hyperandrogenism and impaired glucose tolerance, as well as chronic inflammation, exposing them to an increased risk of cardiovascular diseases. However, the degree to which these hormonal and metabolic alterations persist after menopause (MP) is not well documented.
OBJECTIVE: Our objective was to explore whether adverse metabolic and hormonal alterations persist after MP in women with PCOS.
DESIGN: We conducted a cross-sectional university hospital-based study. PATIENTS AND
INTERVENTIONS: Twenty-one pre-MP (n = 10) and post-MP (n = 11) women diagnosed with PCOS were compared with 29 healthy controls (pre-MP, n = 11; post-MP, n = 18). Two-hour oral glucose tolerance tests were performed, and ovarian steroid secretion capacity was assessed (human chorionic gonadotropin tests). Areas under the curves (AUC) were calculated.
RESULTS: Both pre-MP and post-MP women with PCOS had increased insulin response in oral glucose tolerance tests (AUC(ins) pre-MP = 6733.7 vs. 3382.9; post-MP = 9732.1 vs. 3265.3) and were more insulin resistant than controls. Androgen secretion capacity was increased before and after MP in PCOS (AUC of androstenedione; pre-MP: 1218.4 vs. 853.2; post-MP: 1000.0 vs. 531.3). High-sensitivity C-reactive protein remained elevated after MP in PCOS (pre-MP: 1.3 vs. 0.7; post-MP: 1.4 vs. 0.9 mg/liter). Adjustment for body mass index did not alter the results except for glucose metabolism.
CONCLUSIONS: The results indicate that impaired glucose metabolism, enhanced ovarian androgen secretion, and chronic inflammation observed in pre-MP women with PCOS persist after menopausal transition emphasizing life-long health risks related to this syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21450988     DOI: 10.1210/jc.2011-0039

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

Review 1.  Polycystic ovary syndrome in 2011: Genes, aging and sleep apnea in polycystic ovary syndrome.

Authors:  Andrea Dunaif
Journal:  Nat Rev Endocrinol       Date:  2011-12-20       Impact factor: 43.330

Review 2.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 3.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

Review 4.  Cardiovascular and metabolic risks associated with PCOS.

Authors:  Rhoda H Cobin
Journal:  Intern Emerg Med       Date:  2013-04       Impact factor: 3.397

5.  Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Authors:  Noha M Shawky; Chetan N Patil; Carolina Dalmasso; Rodrigo O Maranon; Damian G Romero; Heather Drummond; Jane F Reckelhoff
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

6.  Hyperandrogenic oligomenorrhea and metabolic risks across menopausal transition.

Authors:  Alex J Polotsky; Amanda A Allshouse; Sybil L Crawford; Sioban D Harlow; Naila Khalil; Rasa Kazlauskaite; Nanette Santoro; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

7.  Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause.

Authors:  Corrine K Welt; Enrico Carmina
Journal:  J Clin Endocrinol Metab       Date:  2013-09-24       Impact factor: 5.958

Review 8.  Reactive oxygen species: players in the cardiovascular effects of testosterone.

Authors:  Rita C Tostes; Fernando S Carneiro; Maria Helena C Carvalho; Jane F Reckelhoff
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-11-04       Impact factor: 3.619

9.  Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm.

Authors:  Marika Paalanne; Marja Vääräsmäki; Sanna Mustaniemi; Marjaana Tikanmäki; Karoliina Wehkalampi; Hanna-Maria Matinolli; Johan Eriksson; Marjo-Riitta Järvelin; Laure Morin-Papunen; Eero Kajantie
Journal:  Eur J Endocrinol       Date:  2021-07-01       Impact factor: 6.664

10.  Polycystic Ovarian Syndrome and Menopause in Forty Plus Women.

Authors:  Sudhaa Sharma; Neha Mahajan
Journal:  J Midlife Health       Date:  2021-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.